Clinical Trials Browser

Rectal Neoplasms × pembrolizumab × 30 days × Clear all

NCT05217446 2026-04-07

SEAMARK

Phase 2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms